News | February 07, 2023
Alembic Pharmaceuticals Q3 FY23 revenue up 19% to Rs. 1,509 Cr
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Through lifestyle modifications, ADORE will assess the progress of patients based on parameters like reduction in blood sugar levels and weight, among others
The inspection of the facility resulted in issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site
Subscribe To Our Newsletter & Stay Updated
